B&W Equine Group has opened a brand new, state-of-the-art equine clinic at Breadstone in Gloucestershire.

The new facility opened on 1 October 2011. It cost over £2.2 million and is, according to the company, one Europe’s most advanced diagnostic and surgical centres.

B&W Equine Group was created in 2008, following a merger between Willesley Equine Clinic and Bushy Equine Vets. The 23 vet practice has four local equine clinics in Breadstone, Cardiff, Failand and Willesley.

The new clinic, located on a four acre site at Breadstone, close to the M4 and M5 intersections, provides state-of-the-art diagnostics and advanced laboratory facilities. It houses the only equine MRI scanner in Wales and the South West, as well as a CT scanner and scintigraphy unit. Orthopaedic and colic theatres, adult and neonatal intensive care suites and separate isolation units have all been custom-designed and are supported by five examination rooms and two knock down boxes.

Clinical and referral services are led by RCVS and European Recognised Specialists in surgery, orthopaedics, diagnostic imaging and internal medicine and include gynaecological management of breeding mares and pre-season disease screening. The on-site laboratory is one of only 30 in the UK to be certified by the HBLB to test for CEM and EVA.

Ian Camm, BVSc CertEP MRCVS, Group Director, said: “We are all extremely excited about the new clinic but our day-to-day first opinion work remains a top priority. For all our local clients it’s very much a case of business as usual but the fact that we have invested in the latest portable equipment, including video endoscopes, digital radiography and ultrasound scanners, means we can undertake more specialist work at client’s yards, as and when needed.”

For further information, visit www.bwequinevets.co.uk.

The Veterinary Marketing Association has announced details of a new award for public relations, open to veterinary practices and companies.

The VMA says this award is to recognise the value that media and public relations can add to the marketing mix. It will be awarded to the company or veterinary practice that has delivered the most innovative PR campaign during 2011, as judged by a panel of industry professionals.

Organiser Claire Edmunds said: "The VMA Awards has become a coveted event for those involved in the animal health industry to showcase their marketing achievements. A range of categories has evolved since the awards began over 20 years ago, for marketing, creative communication and new media campaigns. However, we felt that an award for PR was required to complete the marketing mix".

Jane Manning from award sponsor Splash Marketing & Communications said: "We felt it was time to give the opportunity for those involved in PR to obtain the recognition they deserve alongside their creative colleagues.

"An effective PR campaign can be a highly influential marketing tool, so it's great news that the VMA has added this new award category. We hope that companies and agencies serving the animal health sector will embrace this new opportunity to showcase their creativity and hard work".

The award is for the most innovative PR initiative published during the year. This can be a single 'one-off' event or article, or a sustained campaign over a given period. The winner and two highly commended entries will be awarded at the VMA Awards on Friday 9th March 2012 at Shakespeare's UnderGlobe Theatre, London.

Further information on the awards and ticket application forms are available at the VMA's website - http://www.vma.org.uk/  or by calling 0844 561 6157. The deadline for entries is Friday 27^th January 2012.

A research project funded by equine charity The Horse Trust has found that lameness is the most common reason for euthanasing a geriatric horse.

According to the charity, this research is the first in the UK to provide data on the causes of death in geriatric horses. Although post-mortem studies have provided some data regarding causes of death, "old age" was previously reported as a common reason for the euthanasia of adult horses.

The research was carried out by Joanne Ireland at the University of Liverpool and led by Dr Gina Pinchbeck. Ireland surveyed horse owners living in the North-West and Midlands areas of England and North Wales who have a horse aged 15 years or older. 918 owners of geriatric horses were followed in a cohort study and 118 mortalities were reported during the 18 month follow-up period, of which 111 were euthanased.

The researchers found that 24% of horses were euthanased due to lameness; an additional 12% were euthanased due to laminitis - a common cause of lameness. After lameness, colic was the next most common cause of euthanasia, with 21% of owners citing this as the main reason.

In an earlier stage of the project, the researchers had found that half the geriatric horses surveyed suffered from lameness, but only 24% of owners reported the problem.

Dr Pinchbeck said: "Although lameness is common in older horses, this is the first study to quantify its contribution to their mortality.

"Owners are often missing the early signs of lameness in their horse, which means the condition isn't being managed and may deteriorate faster."

Dr Pinchbeck said it would be useful to carry out further research into lameness in geriatric horses to find out the main causes of lameness and how these may be prevented or treated.

The research team also found that half of the horses euthanased were suffering from concurrent health problems and these influenced the owner's decision to euthanase in 43% of cases. The most frequently reported additional health problems were musculoskeletal problems, such as arthritis.

The mortality rate among the horses surveyed was 11 per 100 horse-years at risk, meaning that if 100 geriatric horses were followed for a year, an average of 11 would die. The mortality rate for horses over 30 years of age was over five times the rate than in horses aged 15 - 19 years.

Jeanette Allen, Chief Executive of The Horse Trust, said the data provided by this research is likely to provide useful information for both horse owners and vets to enable them to improve the welfare of older horses. She said: "As there are a significant number of geriatric horses in the UK, it is vital that we understand more about the health problems that affect them. We hope that more owners of older horses will give their horse an annual health-check to enable the horse to have a longer, healthier life."

The research was published in the September 2011 issue of Preventive Veterinary Medicine.

Pfizer is giving away a free equine weigh tape with every purchase of Equest & Equest Pramox (while stocks last), to help encourage accurate treatment against encysted small redworms this season.

According to the company, Equest & Equest Pramox are the only wormers in the UK that treat encysted small redworm in a single dose. Using a weigh tape to work out their horse's weight will help your clients avoid under dosing, which increases the risk of resistance development.

Pfizer says small redworms are the most common worms found in horses today. They can pose a very serious health risk to horses and it's important for owners to make sure that they are treated properly during the autumn or early winter.

Small redworms can grow up to 2.5cm in length and are thin and reddish in colour. Small redworm eggs are passed in the faeces and then hatch on pasture and continue to develop into more advanced larval stages before being ingested by the horse as it grazes. The larvae burrow deeply into the wall of the gut where they encyst and may account for up to 90% of the redworm burden in the horse¹. Encysted small redworm will not show up in a Faecal Worm Egg Count - even if the horse has shown a negative or low count it could still be harbouring several million encysted small redworms².

Encysted small redworms can remain dormant inside a horse for up to two years, but they usually 'wake-up' in late winter or early spring, developing and emerging from the gut wall all at the same time. In severe infestations mass emergence can lead to a disease syndrome known as 'larval cyathostominosis', causing diarrhoea and colic with up to a 50% mortality rate³. Young horses of less than six years of age can often be at higher risk of the disease³ but small redworm can cause life-threatening illness at any time of year and in any age of horse.

Ben Gaskell, Pfizer's veterinary adviser said: "Treating encysted small redworms successfully in the late autumn or early winter is important to avoid the risk of larval cyathostominosis. It's important to advise your customers to choose a product that is licensed to treat the worms they are targeting and that they give the correct dose, by weighing their horse beforehand, as this will help preserve the efficacy of the drug used."

Pfizer's Does your wormer measure up campaign is backed with point of sale materials and a media campaign. To receive a free weigh tape, valued at £7 your clients need to buy a tube of Equest or Equest Pramox, fill in an application form and send Pfizer the batch and expiry flap from the pack. Pfizer will then send them a FREE Weigh Tape while stocks last.

For further information contact your Pfizer Account Manager.

References

1. Bairden K. et al (2001) Veterinary Record 148, 138-141
2. Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑242
3. McWilliam H. et al (2010) International Journal for Parasitology 40, 265-275

Elanco has announced the results of a challenge study which the company says demonstrates the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course¹.

The study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two dose of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Richmond/1/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.

According to Elanco, this is believed to be the first demonstration of cross protection by a current UK equine influenza vaccine against a Florida sub-lineage clade 2 reference strain.

The OIE (World Organisation for Animal Health) updated its equine influenza vaccine recommendations in 2010 to reflect the fact that all field strains characterised through 2008 and 2009 were of clade 1 or 2 of the Florida sub-lineage. The antigenic difference between viruses of these clades could potentially compromise the effectiveness of vaccines containing a representative of a single clade².

Anna Jackson, national veterinary manager for Elanco Companion Animal Health, said:  "Whilst no vaccine has been updated to match the current OIE recommendations, the results of this challenge study provide reassurance that horses vaccinated with Duvaxyn will be protected against clinical signs of disease caused by currently circulating strains of equine influenza, including those the OIE have identified as being of concern."

Duvaxyn IE-T Plus is an inactivated whole virus equine influenza vaccine, adjuvanted with an aqueous-based adjuvant. Elanco says that experts in the field of human vaccination have expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly-based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins in the vaccine³.

References:

• 1. ECAH study: AHT study ID C012/01
• 2. OIE. Office International des Epizooties Bulletin (2010), 2 pp.44-45
• 3. Meeting Notes: 3rd WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials, 15-16 February 2007, WHO, Geneva

The Veterinary Development Council (VDC) is conducting a survey to investigate the role of paraprofessionals and technicians in veterinary practice, and is asking vets in large animal, equine, and mixed practices to complete a short survey.

The VDC says that information from the survey will help inform discussions on the regulation of technicians.

The survey will take between 5 and 10 minutes to complete and can be found on the BVA website at www.bva.co.uk/vdc. The BVA has also emailed the survey directly to practices.

The survey has been devised by the VDC working group looking at the role of the veterinary-led team, chaired by BVA Past President Professor Bill Reilly. This is one of three working groups that will report to the VDC:

• Veterinary engagement with the food supply chain chaired by Gwyn Jones of the National Farmers' Union (NFU). To consider how the veterinary profession might better engage with the food industry, with a view to better defining what food industry stakeholders need and want in terms of veterinary services, now and in the future and the implications of this for the veterinary profession. The group will also examine ways in which better engagement with food industry stakeholders might be facilitated.
• Business models for the provision of veterinary services chaired by John Fishwick, President of the British Cattle Veterinary Association (BCVA). To identify and classify different business models for veterinary practices and the provision of veterinary services, to consider the merits and limitations of each of these models and provide case studies of their successful application. This group will examine the whole range of models, recognising that one size does not fit all and acknowledging the differences between large and small practices.
• The role of the veterinary-led team chaired by Prof Bill Reilly, Past President of the BVA. To identify the range of services that could be supplied to the farming community by a veterinary-led team, including those services that could be undertaken by veterinarians and non-veterinarians. To identify how these services are currently delivered and to describe the benefits of bringing non-veterinarians into a veterinary-led team. The working group will also assess desire of veterinarians and non veterinarians to work together to deliver these services.

Professor Reilly said: "The relationship between veterinary surgeons and technicians is vital but it varies from practice to practice.

"The working group on the role of the veterinary-led team aims to take a snapshot of how services, such as artificial insemination and foot trimming, are currently delivered, and gauge how veterinary surgeons feel about other services being delivered by non-veterinarians in the future.

"I hope veterinary surgeons in large, mixed and equine practice will take 10 minutes to complete our survey to help us map the current use of technicians in veterinary practice and help shape our future discussions."

Dechra Veterinary Products has launched Celox Veterinary, a product which stops arterial or venous haemorrhage within 3 minutes, described as 'revolutionary' by the company.

Celox Veterinary is available in both a granule formulation and in two sizes of gauze. The granules can be poured into a wound. Once pressure is applied, a clot forms and arterial and venous haemorrhage is stopped within three minutes, independent of the body's normal clotting processes. Celox Veterinary Gauze has the granules ready bonded onto its surface for ease of use.

Dechra says the product works by bonding with red blood cells and gelling with fluids to produce a robust clot which sticks to moist tissue to plug the bleeding site. It can be helpful in treating a wide range of veterinary cases including:

• Haemorrhage following sharp debridement
• Field trauma
• Arterial or venous bleeding
• Severe high pressure bleeding
• Dental bleeds

Celox Veterinary is made from chitosan, a natural polysaccharide and by-product of the shrimp industry.  It generates no heat while in use and small amounts of residual material left in the body are naturally metabolised. 

Dechra Product Manager Rachel Horton said: "Wound care is an area in which Dechra is known for its innovative product range. We are delighted to take this to the next level by offering this revolutionary treatment to vets and believe it will soon establish itself as an efficacious tool when they are faced with significant injuries and severe bleeding."

For further information on Celox Veterinary, please contact your Territory Manager or call Dechra direct on (01939) 211200.

Kruuse UK has announced that it will be launching its new Android telemetric ECG system at BEVA 2011.

The original Televet 100 supports transmission of ECG data to a range of approx 100m (330ft), allowing recording and displaying of real time data only within a confined lunging or riding arena. By linking this system to a mobile network via 3G Android phone and a Windows 7 based tablet PC, the new Televet system overcomes this range limitation.

The new system requires the rider/horse to carry a 3G mobile phone which transmits data over the mobile internet, allowing the veterinary surgeon to display and record real time data on any PC/laptop with internet access or mobile internet connection. This also includes GPS information collected by the phone allowing the ECG, heart rate and velocity of the horse to be displayed in parallel.

The Android Telemetric ECG system is specifically targeted towards veterinary applications in the field of sports horses where extended range is particularly useful, such as endurance riding, three day eventing and racing.

Televet software can now also be integrated in Dicom infrastructures in practice for data capture and recording.

Sarah Stokes, Kruuse Equine Territory Manager said: "the flexibility and simplicity of the system along with immediate access to ECG data of patients will be an invaluable diagnostic tool for UK vets allowing vital support for patients and owners wherever they are."

Visitors to the Kruuse stand at BEVA 2011 will also have the chance to win an Acer ICONI W500 tablet worth £500.

Kruuse is to launch a new Manuka honey dressing at BEVA 2011 in September.

Kruuse says that honey has been used as a topical anti-microbial agent and dressing for over 2000 years, and that honey derived from the nectar of the Manuka tree (Leptospermum scoparium) has its own unique chemical properties. Manuka honey contains glucose oxidase imparted by the bees during its collection and storage. This enzyme facilitates low level release of hydrogen peroxide when in the presence of wound exudates and thus supports cellular proliferation and metabolism through an antioxidant effect. The high sugar and low pH content creates a high osmotic potential which gives honey excellent debridement and anti-inflammatory properties.

The company says that one of the biggest difficulties with the use of honey in wound dressings is ensuring that once applied it stays over the wound area. Many attempts to coat dressings have been unsuccessful; often the active honey ingredient is left within the packaging severely reducing the effectiveness of the dressing. Kruuse says its Manuka dressings have the active honey impregnated 'within' the dressing, which ensures precise and easy application even if wearing surgical gloves.

The Kruuse Manuka dressings range comes in impregnated adherent (Kruuse Manuka AD), non-adherent dressing (Kruuse Manuka ND) and 15g tube of Manuka G.  Each dressing comes in 3 sizes 5x5 cm , 10x12.5 cm and the KRUUSE Manuka roll (10x100 cm) a unique product ideal for large vertical wounds. E.G. Equine forelimb.

Kruuse also says that the antimicrobial potency in Manuka honey is rated by a standardised rating known as Unique Manuka Factor (UMF). The higher the UMF the better the antimicrobial effect.  A minimum UMF of 10 is required to ensure sufficient effect in the wound environment, Kruuse Manuka Honey Wound Dressings have a Unique Manuka Factor of 15.

There is a restricted annual supply of Manuka honey as this unique product supply is controlled by a small number of producers in New Zealand. Many current honey products available use blends of Manuka honey with other poorer quality honey, these are often less effective. Kruuse Manuka uses 100% Manuka honey in all its dressings with the profits of the sale being returned directly to the Maori tribe that oversee the production of Manuka honey.

Andrew Groom, Managing Director Kruuse UK Ltd. said: "I am very excited that we have been able to secure a direct connection to supply this unique product with the knowledge that the Maori suppliers will see the returns for generations to come whilst this new range of dressing will add huge versatility for day to day wound management!"

Pfizer Animal Health has launched PrintRoom, an online printing service to help equine practices deliver high quality communications to their clients, to support the company's Equip range of equine vaccines.

PrintRoom can be used to produce customised vaccination reminder cards, invitations, letterheads, stable name sheets, and more.

You can choose from a palette of designs, images and colours and can also upload your own logos and images to tailor your client communications to your preferred style.

PrintRoom has a MailMerge option to pre-address all your mailings and you can pay for postage and set the date of despatch online, to help ensure boosters are administered on time and passports stay up to date.

Paul Blanc, Equine Brand manager at Pfizer said: "Good communication with your clients plays a vital role in maintaining vaccination compliance and retaining and gaining business. Our print room service makes it easy to produce a broad range of customised practice marketing materials to a very professional standard that stand out from the crowd."

For further information visit http://www.pfizerprintroom.com/, call 0845 6027439 or contact your Pfizer Account Manager.

Pfizer has repeated it's call for veterinary practice staff to take part in its Vet Support+ independent, industry-wide survey of employee engagement.

The survey gives practice team members, who are not partners or owners, the chance to have their say about their role and career and the future of the profession. Participants are asked to consider how they feel towards their practice and delve into issues on teamwork and communication, management techniques, personal development opportunities and working environment.

More than 3,000 vet practice staff have already completed the survey, a phenomenal early response which suggests practice employees are keen to have their voices heard. However, the closing date for the survey isn't till Friday 29th July, so if you haven't yet had a chance to do the survey, there is still time.

Pfizer Business Consultant, Vanessa Wilson, has more than 20 years experience helping businesses, teams and individuals achieve their goals. She is not surprised at the significant early response: "Questions on the level of employee engagement and satisfaction come up all the time in the work we do with practices. I'm not surprised that staff are using this opportunity to have their voice heard.

"Once completed, this survey will provide some very useful data and direction for the industry as a whole and I'd like to think it will identify opportunities for both individual career development and practice growth."

All members of staff employed within a practice who have not received a mailing and wish to participate are welcome to respond online. http://www.noesis-mi.com/surveys/employeesurvey/.

Pfizer says the findings, which are expected to be released in the autumn, will deliver a national and regional view of the current employee engagement landscape.

For further information about Vet Support+ Business Services from Pfizer visit www.vetsupportplus.co.uk.

BCF Technology has launched a competition in which the person who submits the best photograph with the theme of: All in a day's work - animal imaging, will win an iPad 2.

To enter the competition, you need to post your photographs, (and tell BCF a little about the story behind the images) at www.facebook.com/bcftechnology or email them to: info@bcftechnology.com

Jason Rogers, Marketing Manager at BCF said: "We wanted to create a fun way to show just how interesting and different each days work is when imaging animals. We have made the competition open to all that work with animal imaging including our staff, dealers and vets, vet nurses, animal contractors, etc from all over the world.  

"It is great to see the BCF office in the States and our international dealers also promoting the competition in their own countries, making the competition truly international. Response to the competition has been fantastic - see our facebook page to some entries for yourself."

The closing date for the competition is 30^th September 2011.

For more information, visit: www.bcftechnology.com

The National Office of Animal Health has completed its annual review of its Code of Practice for the Promotion of Animal Medicines, and a number of changes will come into effect on 1st July 2011.

One change spells out the way antimicrobial medicines are promoted to farmers, with a firm emphasis on correct use and education.

Advertisers will be required to describe the condition the product is aiming to treat, and to promote an understanding of the treatment of the disease.

The phrase "use medicines responsibly" will always be included in text, making the voluntary strapline introduced in 2009 a formal part of the NOAH Code. As with all promotions to people other than prescribers, farmers will always be reminded to consult their veterinary surgeon.

Advertising text will always state clearly the name of the company and the brand being promoted, and promotion must not be designed to disguise its real nature.

Withdrawal periods for products will be stated, but these must not be unduly prominent and not in a font size greater than the body copy containing recommended dosage and species description.

The changes were proposed by NOAH within its formal response to the Veterinary Medicines Directorate's consultation on the Veterinary Medicines Regulation 2010. The Minister decided in December 2010 to continue to allow the advertising of antimicrobial veterinary products to farmers.

Phil Sketchley, NOAH Chief Executive, said: "Whilst welcoming the Government's decision in December not to further restrict the advertising of animal medicines, we feel that the industry should take a proactive role to ensure the system works properly. We believe it is important for farmers, who are legally responsible for the health and welfare of their animals and the food produced from them, to be aware of the medicines that are available to protect the health of their animals, and at the same time we want them to know that these medicines must be prescribed and used responsibly.

"The issue of antimicrobial resistance is one that affects us all. The way to promote best practice is through education by maintaining all lines of communication between farmers, vets, scientists and animal medicine producers.

"Antibiotics are essential for maintaining the health and welfare of all animals, but like any medicine they need to be used responsibly in order to maintain their effectiveness, and their availability for future generations."